• Jun-Li Bao, Xinyuan-Gao Heilongjiang University of Chinese Medicine, No.24, Heping Road, Xiangfang District, Haerbin., Yu-Bo Han, Ke Zhang, and Li Liu.
• Heilongjiang University of Chinese Medicine, No.24, Heping Road, Xiangfang District, Haerbin.
• Medicine (Baltimore). 2021 Jan 22; 100 (3): e23958.

BackgroundPediatric obstructive sleep apnea syndrome (OSAS) is significant public concern. Clinical practice indicates that montelukast has certain therapeutic advantages, while there is a lack of evidence-based medicine support. The aim of this study is to synthesize related data to explore efficacy and safety of montelukast for pediatric OSAS.MethodsData in Pubmed, EMBASE, CENTRAL, CBM, CNKI, WanFang, VIP databases were comprehensively searched. All the randomized controlled trials (RCTs) in OSAS children were identified, in which the effects of montelukast on a range of outcomes were compared. The search had a deadline of January 1, 2020. Two investigators independently conducted data extraction and assessed the literature quality of the included studies. The Revman5.3 software was used for meta-analysis of the included literature.ResultsThe efficacy and safety of montelukast in the treatment of pediatric OSAS were evaluated in terms of apnea hypopnea index (AHI), the Pittsburgh Sleep Quality Index, the Epworth Sleep Scale (ESS), neck circumference, important index in Polysomnography: sleep efficiency, desaturation index, total sleep time.ConclusionsThis study provides reliable evidence-based support for the clinical application of montelukast in the treatment of pediatric OSAS.Prospero Registration NumberCRD42020146940.Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

35 keywords...

hide…